Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus

Caribou Biosciences, Inc.

2024-Q1 EPS reported -$0.46 revenue$2,429,000

Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.
Cash, cash equivalents, and marketable securities $345.9M as of Mar 31, 2024, funding operations into Q1 2026.
FDA IND clearance for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 trial expected to start by YE 2024.
Plans to present initial CB-010 dose expansion data at ASCO June 3, 2024; initial CB-011 data by YE 2024.
Licensing and collaboration revenue $2.4M, down from $3.5M due to terminated AbbVie agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $2.4 million.

Period: the quarter ended March 31, 2024
Revenue: $2.4 million
Result: reported results

Exact text from the filing

Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $2.4 million for the three months ended March 31, 2024, compared to $3.5 million for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.